Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: J Med Virol. 2017 May 23;89(9):1620–1628. doi: 10.1002/jmv.24809

Figure 4. SB 9200 shows activity against HCV derived from patients who have relapsed after DAA therapy.

Figure 4

Capture fusion assay was performed with sera from G3 patients who had responded (A) or failed to respond (B) to DAA treatment. A single dose [0.1μM] in quadruplicate of either Daclatasvir, Ledipasvir or SB 9200 was used and the fold change for each drug ± s.e.m plotted.